Characteristics of patients with axial spondyloarthritis.
| Characteristics | Patients Included in Analysis, n = 240 | All Enrolled Patients, n = 330 | p |
|---|---|---|---|
| Age, yrs | 37 ± 12 | 37 ± 12 | 0.562 |
| Male | 193 (80) | 267 (81) | 0.914 |
| Symptom duration, yrs | 9 ± 9 | 9 ± 9 | 0.612 |
| HLA-B27-positive | 190 (79) | 262 (79) | 1.000 |
| Smoking status | 0.996 | ||
| Never | 106 (45) | 148 (45) | |
| Ex-smoker | 49 (21) | 67 (21) | |
| Current | 80 (34) | 111 (34) | |
| BASDAI (0–10 scale) | 4.0 ± 2.2 | 4.1 ± 2.2 | 0.787 |
| ASDAS-ESR | 2.7 ± 1.1 | 2.7 ± 1.1 | 0.996 |
| ASDAS-CRP | 2.4 ± 1.3 | 2.4 ± 1.3 | 0.963 |
| ESR, mm/h | 24 ± 21 | 23 ± 21 | 0.658 |
| CRP, mg/l | 10.3 ± 18.5 | 10.3 ± 19.6 | 0.996 |
| Radiographic sacroiliitis | 190 (79) | 262 (79) | 1.000 |
| mSASSS score | 12.2 ± 20.0 | 11.5 ± 19.3 | 0.668 |
| No. syndesmophytes | 4.0 ± 7.1 | 3.8 ± 6.8 | 0.744 |
| Treatment at baseline | |||
| NSAID | 216 (93) | 302 (94) | 0.724 |
| Sulfasalazine | 66 (28) | 102 (32) | 0.401 |
| TNF inhibitor | 48 (21) | 52 (16) | 0.221 |
| TBS | 1.385 ± 0.123 | 1.393 ± 0.122 | 0.404 |
| BMD at lumbar spine | 1.175 ± 0.224 | 1.184 ± 0.214 | 0.624 |
| BMD at femoral neck | 0.932 ± 0.151 | 0.950 ± 1.150 | 0.169 |
| BMD at total hip | 0.969 ± 0.154 | 0.982 ± 0.151 | 0.283 |
Values are n (%) or mean ± SD. BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; mSASSS: modified Stoke Ankylosing Spondylitis Spinal Score; NSAID: nonsteroidal antiinflammatory drugs; TNF: tumor necrosis factor; TBS: trabecular bone score; BMD: bone mineral density.